NCT01522664

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This multicenter, open-label study will assess the safety and pharmacokinetics of DEDN6526A in patients with metastatic or unresectable melanoma. Cohorts of patients will receive escalating doses of DEDN6526A by intravenous infusion on Day 1 of each 21-day cycle. In the absence of disease progression or unacceptable toxicity, patients may continue to receive DEDN6552A for up to 17 cycles (1 year).

Conditions

• Malignant Melanoma

Interventions

Type	Name	Description
DRUG	DEDN6526A	Multiple ascending doses

Timeline

• Start date: 2012-03-01
• Primary completion: 2015-06-01
• Completion: 2015-06-01
• First posted: 2012-01-31
• Last updated: 2016-11-02

Locations

6 sites across 2 countries: United States, Australia